Cargando…

MPL S505C enhances driver mutations at W515 in essential thrombocythemia

Detalles Bibliográficos
Autores principales:	Varghese, Leila N., Carreño-Tarragona, Gonzalo, Levy, Gabriel, Gutiérrez-López de Ocáriz, Xabier, Rapado, Inmaculada, Martínez-López, Joaquín, Ayala, Rosa, Constantinescu, Stefan N.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8630145/ https://www.ncbi.nlm.nih.gov/pubmed/34845187 http://dx.doi.org/10.1038/s41408-021-00583-4

Ejemplares similares

Familial Essential Thrombocythemia Associated with MPL W515L Mutation in Father and JAK2 V617F Mutation in Daughter
por: Trifa, Adrian P., et al.
Publicado: (2014)

MPL W515L/K Mutations in Chronic Myeloproliferative Neoplasms
por: Akpınar, Timur Selçuk, et al.
Publicado: (2013)

Mesenchymal Cell Reprogramming in Experimental MPL(W515L) Mouse Model of Myelofibrosis
por: Han, Ying, et al.
Publicado: (2017)

Prefibrotic Myelofibrosis Presenting with Multiple Cerebral Embolic Infarcts and the Rare MPL W515S Mutation
por: Langabeer, Stephen E., et al.
Publicado: (2020)

Nonfamilial, MPL S505N-Mutated Essential Thrombocythaemia
por: Morrell, Ruth, et al.
Publicado: (2013)

A Rare Case of Essential Thrombocythemia with Coexisting JAK2 and MPL Driver Mutations
por: Jang, Mi-Ae, et al.
Publicado: (2020)

MPL-mutated essential thrombocythemia: a morphologic reappraisal
por: Szuber, Natasha, et al.
Publicado: (2018)

An MPL W515L mutation in refractory anemia with ringed sideroblasts associated with marked thrombocytosis: A case report
por: HAO, LIN, et al.
Publicado: (2015)

MPL W515L expression induces TGFβ secretion and leads to an increase in chemokinesis via phosphorylation of THOC5
por: Whetton, Anthony D., et al.
Publicado: (2016)

Tyrosine 625 plays a key role and cooperates with tyrosine 630 in MPL W515L-induced signaling and myeloproliferative neoplasms
por: Yu, Chunjie, et al.
Publicado: (2016)

MPL mutations and palpable splenomegaly are independent risk factors for fibrotic progression in essential thrombocythemia
por: Haider, M, et al.
Publicado: (2016)

Monitoring of clonal evolution of acute myeloid leukemia identifies the leukemia subtype, clinical outcome and potential new drug targets for post-remission strategies or relapse
por: Onecha, Esther, et al.
Publicado: (2020)

Prevalence of MPL (W515K/L) Mutations in Patients with Negative-JAK2 (V617F) Myeloproliferative Neoplasm in North-East of Iran
por: Shams, Seyyede Fatemeh, et al.
Publicado: (2018)

Cytogenetics, JAK2 and MPL mutations in polycythemia vera, primary myelofibrosis and essential thrombocythemia
por: dos Santos, Leonardo Caires, et al.
Publicado: (2011)

Selected Parameters of Angiogenesis and the JAK2, CALR, and MPL Mutations in Patients With Essential Thrombocythemia
por: Gadomska, Grażyna, et al.
Publicado: (2018)

Familial Essential Thrombocythemia With Novel MPL L502G and G208K Mutations
por: Rendo, Matthew, et al.
Publicado: (2022)

Tuning MPL signaling to influence hematopoietic stem cell differentiation and inhibit essential thrombocythemia progenitors
por: Cui, Lu, et al.
Publicado: (2021)

Occurrence of a paroxysmal nocturnal hemoglobinuria clone in an essential thrombocythemia: a link between PIGV and MPL
por: Knaus, Alexej, et al.
Publicado: (2022)

A Multiplex Snapback Primer System for the Enrichment and Detection of JAK2 V617F and MPL W515L/K Mutations in Philadelphia-Negative Myeloproliferative Neoplasms
por: Wu, Zhiyuan, et al.
Publicado: (2014)

JAK2 V617F, MPL, and CALR Mutations in Korean Patients with Essential Thrombocythemia and Primary Myelofibrosis
por: Kim, Bo Hyun, et al.
Publicado: (2015)

Driver mutations (JAK2V617F, MPLW515L/K or CALR), pentraxin-3 and C-reactive protein in essential thrombocythemia and polycythemia vera
por: Lussana, Federico, et al.
Publicado: (2017)

Significance of combined detection of JAK2V617F, MPL and CALR gene mutations in patients with essential thrombocythemia
por: Ji, Liying, et al.
Publicado: (2017)

Clinical and Hematological Relevance of JAK2V617F, CALR, and MPL Mutations in Vietnamese Patients with Essential Thrombocythemia
por: Vu, Hoang Anh, et al.
Publicado: (2019)

Screening of JAK2 V617F and MPL W515 K/L negative essential thrombocythaemia patients for mutations in SESN2, DNAJC17, ST13, TOP1MT, and NTRK1
por: AL Assaf, Carla, et al.
Publicado: (2014)

Treatment of Refractory Anemia with Ring Sideroblasts Associated with Marked Thrombocytosis with Lenalidomide in a Patient Testing Negative for 5q Deletion and JAK2 V617F and MPL W515K/L Mutations
por: Keen, Ryan, et al.
Publicado: (2016)

MPL Y252H anMd PL F126fs mutations in essential thrombocythemia: Case series and review of literature
por: Elsayed, Ahmed G., et al.
Publicado: (2019)

Clinical Manifestation of Calreticulin Gene Mutations in Essential Thrombocythemia without Janus Kinase 2 and MPL Mutations: A Chinese Cohort Clinical Study
por: Sun, Chao, et al.
Publicado: (2016)

Recent advances in understanding myelofibrosis and essential thrombocythemia
por: Vainchenker, William, et al.
Publicado: (2016)

Systematization of analytical studies of polycythemia vera, essential thrombocythemia and primary myelofibrosis, and a meta-analysis of the frequency of JAK2, CALR and MPL mutations: 2000–2018
por: Mejía-Ochoa, Mónica, et al.
Publicado: (2019)

Comparison of the effects between MPL and JAK2V617F on thrombosis and peripheral blood cell counts in patients with essential thrombocythemia: a meta-analysis
por: Yang, Erpeng, et al.
Publicado: (2021)

Impact of IPSS-M implementation in real-life clinical practice
por: Zamanillo, Irene, et al.
Publicado: (2023)

Application of IPSET-thrombosis in 1366 Patients Prospectively Followed From the Spanish Registry of Essential Thrombocythemia
por: Alvarez-Larrán, Alberto, et al.
Publicado: (2023)

505 Verdades publicitarias /
por: Pratt Gaballí, Pedro
Publicado: (2001)

Mutations in the DNA methylation pathway and number of driver mutations predict response to azacitidine in myelodysplastic syndromes
por: Cedena, M. Teresa, et al.
Publicado: (2017)

c-Mpl-del, a c-Mpl alternative splicing isoform, promotes AMKL progression and chemoresistance
por: Li, Fei, et al.
Publicado: (2022)

Multidisciplinary management in chronic myeloid leukemia improves cardiovascular risk measured by SCORE
por: Blanco Sánchez, Alberto, et al.
Publicado: (2023)

Correction: Mutations in the DNA methylation pathway and number of driver mutations predict response to azacitidine in myelodysplastic syndromes
por: Cedena, M. Teresa, et al.
Publicado: (2018)

TPO/Mpl Studies in Agnogenic Myeloid Metaplasia
por: Hemavathy, Kirugaval C, et al.
Publicado: (2005)

The Main (Glyco) Phospholipid (MPL) of Thermoplasma acidophilum
por: Freisleben, Hans-Joachim
Publicado: (2019)

Essential thrombocythemia
por: Brière, Jean B
Publicado: (2007)

Cannot write session to /tmp/vufind_sessions/sess_hvnhuefnihcocvf8fsts6enbt9